Research and innovation focused on improving lives

Mayo Clinic is a leader in developing new uses for nuclear medicine to improve the diagnosis and treatment of adults and children with serious or complex conditions.

Mayo Clinic was one of the first medical institutions in the United States to offer a new treatment for people with certain neuroendocrine tumors affecting the digestive tract. The treatment, lutetium Lu 177 dotatate (Lutathera), was approved in January 2018 by the FDA for adults with advanced neuroendocrine tumors that affect the pancreas or gastrointestinal tract, known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

The Mayo Clinic Division of Nuclear Medicine is one of a very few programs at select medical centers with experts trained and certified to provide Lutathera. Mayo Clinic was one of the centers to treat people in the landmark clinical trial that led to FDA approval of this therapy.

See a list of publications by Mayo Clinic physicians on PubMed, a service of the National Library of Medicine.

An opportunity to be part of research

If you are eligible to undergo nuclear medicine therapy at Mayo Clinic, your doctor might invite you to be part of one of multiple clinical trials. Programs such as the Early Cancer Therapeutics Group offer options if your cancer hasn't responded to standard treatments.

Aug. 25, 2020
  1. Johnson GB (expert opinion). Mayo Clinic. March 9, 2020.
  2. Kendi AT (expert opinion). Mayo Clinic. May 29, 2019.
  3. Office of Patient Education. Peptide receptor radionuclide therapy (PRRT) for somatostatin-positive tumors. Mayo Clinic; 2018.
  4. Strosberg J, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. New England Journal of Medicine 2017; doi:10.1056/NEJMoa1607427.
  5. U.S. Food and Drug Administration (news release). FDA approves new treatment for certain digestive tract cancers. Jan. 26, 2018. Accessed May 24, 2018.
  6. National Cancer Institute (news release). FDA approves new treatment for certain neuroendocrine tumors. Feb. 8, 2018. Accessed May 24, 2018.
  7. Warner KJ. Allscripts EPSi. Mayo Clinic. April 29, 2019.
  8. Kendi AT, et al. Therapy with 177Lu-DOTATE: Clinical implementation and impact on care of patients with neuroendocrine tumors. American Journal of Roentgenology. 2019; doi:10.2214/AJR.19.21123.
  9. Halfdanarson, TR (expert opinion). Mayo Clinic. March 11, 2020.